First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light

Christoph Jakob Ackermann; Martin Reck; Luis Paz-Ares; Fabrice Barlesi; Raffaele Califano

doi:10.1016/j.lungcan.2019.06.007

First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light

Christoph Jakob Ackermann, Martin Reck, Luis Paz-Ares, Fabrice Barlesi, Raffaele Califano

Research output: Contribution to journal › Review article › peer-review

35 Citations (Scopus)

Abstract

The development of PD-1, PD-L1 and CTLA-4 immune checkpoint inhibitors (CPI) has revolutionised the treatment of advanced non-small cell lung cancer (NSCLC). The potential of immunotherapy (IO) to induce durable responses for a subset of patients represents a therapeutic milestone. After the approval of front-line single agent pembrolizumab, IO-based combinations are rapidly entering clinical practice resulting in a fast change of treatment algorithms for advanced NSCLC. We hereby summarize the recent first-line phase 3 trials evaluating PD-(L)1 blockade plus chemotherapy (ChT) and PD-1 plus CTLA-4 CPI for advanced NSCLC and provide potential treatment recommendations.

Original language	English
Pages (from-to)	245-253
Number of pages	9
Journal	Lung Cancer
Volume	134
DOIs	https://doi.org/10.1016/j.lungcan.2019.06.007
Publication status	Published - 1 Aug 2019
Externally published	Yes

Keywords

Advanced
CTLA-4
Checkpoint inhibitors
Chemotherapy
First-line
Immuno-Oncology
Immunotherapy
NSCLC
Non-Small-Cell Lung Cancer
PD-1
PD-L1

Access to Document

10.1016/j.lungcan.2019.06.007

Cite this

@article{f59dcf590abf4f718abab92e507396d6,

title = "First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light",

abstract = "The development of PD-1, PD-L1 and CTLA-4 immune checkpoint inhibitors (CPI) has revolutionised the treatment of advanced non-small cell lung cancer (NSCLC). The potential of immunotherapy (IO) to induce durable responses for a subset of patients represents a therapeutic milestone. After the approval of front-line single agent pembrolizumab, IO-based combinations are rapidly entering clinical practice resulting in a fast change of treatment algorithms for advanced NSCLC. We hereby summarize the recent first-line phase 3 trials evaluating PD-(L)1 blockade plus chemotherapy (ChT) and PD-1 plus CTLA-4 CPI for advanced NSCLC and provide potential treatment recommendations.",

keywords = "Advanced, CTLA-4, Checkpoint inhibitors, Chemotherapy, First-line, Immuno-Oncology, Immunotherapy, NSCLC, Non-Small-Cell Lung Cancer, PD-1, PD-L1",

author = "Ackermann, \{Christoph Jakob\} and Martin Reck and Luis Paz-Ares and Fabrice Barlesi and Raffaele Califano",

note = "Publisher Copyright: {\textcopyright} 2019",

year = "2019",

month = aug,

day = "1",

doi = "10.1016/j.lungcan.2019.06.007",

language = "English",

volume = "134",

pages = "245--253",

journal = "Lung Cancer",

issn = "0169-5002",

}

TY - JOUR

T1 - First-line immune checkpoint blockade for advanced non-small-cell lung cancer

T2 - Travelling at the speed of light

AU - Ackermann, Christoph Jakob

AU - Reck, Martin

AU - Paz-Ares, Luis

AU - Barlesi, Fabrice

AU - Califano, Raffaele

PY - 2019/8/1

Y1 - 2019/8/1

N2 - The development of PD-1, PD-L1 and CTLA-4 immune checkpoint inhibitors (CPI) has revolutionised the treatment of advanced non-small cell lung cancer (NSCLC). The potential of immunotherapy (IO) to induce durable responses for a subset of patients represents a therapeutic milestone. After the approval of front-line single agent pembrolizumab, IO-based combinations are rapidly entering clinical practice resulting in a fast change of treatment algorithms for advanced NSCLC. We hereby summarize the recent first-line phase 3 trials evaluating PD-(L)1 blockade plus chemotherapy (ChT) and PD-1 plus CTLA-4 CPI for advanced NSCLC and provide potential treatment recommendations.

AB - The development of PD-1, PD-L1 and CTLA-4 immune checkpoint inhibitors (CPI) has revolutionised the treatment of advanced non-small cell lung cancer (NSCLC). The potential of immunotherapy (IO) to induce durable responses for a subset of patients represents a therapeutic milestone. After the approval of front-line single agent pembrolizumab, IO-based combinations are rapidly entering clinical practice resulting in a fast change of treatment algorithms for advanced NSCLC. We hereby summarize the recent first-line phase 3 trials evaluating PD-(L)1 blockade plus chemotherapy (ChT) and PD-1 plus CTLA-4 CPI for advanced NSCLC and provide potential treatment recommendations.

KW - Advanced

KW - CTLA-4

KW - Checkpoint inhibitors

KW - Chemotherapy

KW - First-line

KW - Immuno-Oncology

KW - Immunotherapy

KW - NSCLC

KW - Non-Small-Cell Lung Cancer

KW - PD-1

KW - PD-L1

UR - http://www.scopus.com/inward/record.url?scp=85068367602&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2019.06.007

DO - 10.1016/j.lungcan.2019.06.007

M3 - Review article

C2 - 31319988

AN - SCOPUS:85068367602

SN - 0169-5002

VL - 134

SP - 245

EP - 253

JO - Lung Cancer

JF - Lung Cancer

ER -

First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light

Abstract

Keywords

Access to Document

Other files and links

Cite this